Lundbeck (Germany)

Recent papers from Lundbeck (Germany)

1. Persistence of pharmacological migraine prevention based on statutory health insurance claims data from Germany: a retrospective cohort studyFrontiers in Health Services · 2026
2. Real-world adherence and healthcare resource utilization following transition to aripiprazole once-every-2-months from oral or once-monthly aripiprazole among patients diagnosed with schizophrenia in the United StatesCurrent Medical Research and Opinion · 2026
3. Real-world Improvements in Cognitive Symptoms After Eptinezumab Treatment in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for the Ongoing INFUSE Study (P1-15.006)Neurology · 2026
4. Real-world Effectiveness of Eptinezumab in Patients in Whom ≥1 Prior Anti-CGRP Preventive Treatment had Failed: 6-month Results for an Ongoing Prospective Study (P10-15.006)Neurology · 2026
5. Patient-reported outcomes from a real-world evidence study in individuals with migraine initiating eptinezumab after ≥1 prior calcitonin gene-related peptide (CGRP)-targeted preventive therapyCephalalgia Reports · 2026
6. Evaluating antipsychotic prescribing trends and patient outcomes in schizophrenia and schizoaffective disorder: Insights from a year-long observational study across two tertiary mental health treatment centres in South AustraliaAustralasian Psychiatry · 2026
7. Pyometra management in three mares: The use of endotracheal tubes as cervical stentsEquine Veterinary Education · 2026
8. Vortioxetine’s cardiovascular profile as a relevant feature for the management of major depressive disorder in comorbidity with organic diseasesExpert Review of Neurotherapeutics · 2025
9. Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in SwitzerlandCNS Drugs · 2025
10. Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countriesExpert Review of Pharmacoeconomics & Outcomes Research · 2025
11. Predictors of symptomatic and wellbeing remission in real-world samples of patients living with schizophrenia treated with aripiprazole once-monthly by means of constrained confidence partitioningSchizophrenia Research · 2025
12. Effectiveness of 8-week TReatment with vortioxetine on depressive symptoms in major depressive disorder patients with comorbid generalized anxiety disorder in UAE (TRUE)Annals of General Psychiatry · 2024
13. Depersonalization/derealization and its relationship to mood and anxiety disorders in the National Comorbidity Survey-Replication (NCS-R)2024
14. Abstracts from the 17th European Headache Congress (EHC)The Journal of Headache and Pain · 2024
15. Treatment with Eptinezumab Reduces Brain Fog and Increases the Number of Good Days Per Month in Patients with Chronic Migraine in a Real-world Setting (P8-12.009)Neurology · 2024
16. Shift in MHDs below the threshold of preventive optimization after eptinezumab treatment in patients with migraine and history of 2–4 preventive migraine treatment failures (P5-12.010)Neurology · 2024
17. Long-term Maintenance of ≥50% Migraine Response with Eptinezumab Treatment in Patients with 2–4 Prior Preventive Migraine Treatment Failures (S22.008)Neurology · 2024
18. Impact of Psychiatric Conditions on the Real-world Effectiveness of Eptinezumab Treatment in Patients with Chronic Migraine (P4-12.005)Neurology · 2024
19. Real-world Effectiveness of Intravenous Eptinezumab in Patients with Chronic Migraine and Previous Subcutaneous Preventive Migraine Treatment (P8-12.004)Neurology · 2024
20. Treating Schizophrenia and Bipolar I Disorder in the Real-World SettingThe Primary Care Companion For CNS Disorders · 2024